Type I IFN-mediated regulation of IL-1 production in inflammatory disorders

Cellular and Molecular Life Sciences

Volumn 69, Issue 20, 2012, Pages 3395-3418

  Ludigs, Kristina ^a   Parfenov, Valeriy ^b   Pasquier, Renaud A Du ^b   Guarda, Greta ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Anti IL 1 therapy; Autoimmunity; IL 1; Inflammasome; Inflammatory disorders; Multiple sclerosis; Type I IFN

Indexed keywords

ADAPTOR PROTEIN; AIM2 PROTEIN; ALPHA INTERFERON; ASC PROTEIN; BETA INTERFERON; BETA1A INTERFERON; CRYOPYRIN; EXTRACHROMOSOMAL DNA; GAMMA INTERFERON; HELICASE; INFLAMMASOME; INTERFERON; INTERFERON REGULATORY FACTOR 3; INTERFERON STIMULATED GENE FACTOR 3; INTERFERON TYPE III; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; MELANOMA DIFFERENTIATION ASSOCIATED GENE 5 PROTEIN; NLRC4 PROTEIN; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PROTEIN; RETINOIC ACID INDUCIBLE PROTEIN I; STAT PROTEIN; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; AMINO TERMINAL SEQUENCE; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; ASTHMA; ATOPY; AUTOIMMUNITY; BACTERIAL INFECTION; BACTERIAL SUPERINFECTION; BEHCET DISEASE; CANCER THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILL; CHRONIC MYELOID LEUKEMIA; CROHN DISEASE; CYTOKINE PRODUCTION; DEPRESSION; DIMERIZATION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; ENTERITIS; FAMILIAL MEDITERRANEAN FEVER; FATIGUE; FLU LIKE SYNDROME; FULMINANT HEPATIC FAILURE; HAIRY CELL LEUKEMIA; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOMODULATION; INFLAMMATION; INFLAMMATORY DISEASE; INNATE IMMUNITY; INTERFERON INDUCTION; INTERFERON PRODUCTION; INTRACELLULAR SIGNALING; LEUKOPENIA; LIVER CELL CARCINOMA; LYMPHOCYTE DIFFERENTIATION; MELANOMA; MULTIPLE SCLEROSIS; MYALGIA; MYCOSIS; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SJOEGREN SYNDROME; SOLID TUMOR; SUICIDE ATTEMPT; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; TH17 CELL; TRANSCRIPTION REGULATION; TRANSLATION REGULATION; TUBERCULOSIS; ULCERATIVE COLITIS; VIRUS INFECTION;

ANIMALS; HUMANS; INFLAMMATION; INTERFERON TYPE I; INTERLEUKIN-1;

EID: 84867574317     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-012-0989-2     Document Type: Review

References (347)

1. Medzhitov R (2008) Origin and physiological roles of inflammation. Nature 454(7203):428-435
2. Kawai T, Akira S (2011) Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34(5):637-650
3. Osorio F, Reis e Sousa C (2011) Myeloid C-type lectin receptors in pathogen recognition and host defense. Immunity 34(5): 651-664
4. Elinav E et al (2011) Regulation of the antimicrobial response by NLR proteins. Immunity 34(5):665-679
5. Loo YM, Gale M Jr (2011) Immune signaling by RIG-I-like receptors. Immunity 34(5):680-692
6. Goshen I, Yirmiya R (2009) Interleukin-1 (IL-1): A central regulator of stress responses. Front Neuroendocrinol 30(1): 30-45
7. Dinarello CA (2004) Infection, fever, and exogenous and endogenous pyrogens: Some concepts have changed. J Endotoxin Res 10(4):201-222
8. Rasmussen AK, Bendtzen K, Feldt-Rasmussen U (2000) Thyrocyte-interleukin- 1 interactions. Exp Clin Endocrinol Diabetes 108(2):67-71
9. Dower SK et al (1986) The cell surface receptors for interleukin-1 alpha and interleukin-1 beta are identical. Nature 324(6094): 266-268
10. Stylianou E et al (1992) Interleukin 1 induces NF-kappa B through its type I but not its type II receptor in lymphocytes. J Biol Chem 267(22):15836-15841
11. Leung K et al (1994) The cytoplasmic domain of the interleukin-1 receptor is required for nuclear factor-kappa B signal transduction. J Biol Chem 269(3):1579-1582
12. Croston GE, Cao Z, Goeddel DV (1995) NF-kappa B activation by interleukin-1 (IL-1) requires an IL-1 receptor-associated protein kinase activity. J Biol Chem 270(28):16514-16517
13. O'Neill LA (2008) The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev 226:10-18
14. Dinarello CA (2011) A clinical perspective of IL-1 beta as the gatekeeper of inflammation. Eur J Immunol 41(5):1203-1217
15. Dinarello CA (1996) Biologic basis for interleukin-1 in disease. Blood 87(6):2095-2147
16. Fantuzzi G, Dinarello CA (1996) The inflammatory response in interleukin-1 beta-deficient mice: Comparison with other cytokine-related knock-out mice. J Leukoc Biol 59(4):489-493
17. Yazdi AS et al (2010) Nanoparticles activate the NLR pyrin domain containing 3 (Nlrp3) inflammasome and cause pulmonary inflammation through release of IL-1 alpha and IL-1 beta. Proc Natl Acad Sci USA 107(45):19449-19454
18. Chen CJ et al (2006) MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest 116(8):2262-2271
19. Smith KA, Gilbride KJ, Favata MF (1980) Lymphocyte activating factor promotes T-cell growth factor production by cloned murine lymphoma cells. Nature 287(5785):853-855
20. Sutton C et al (2006) A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med 203(7):1685-1691
21. Acosta-Rodriguez EV et al (2007) Interleukins 1 beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 8(9):942-949
22. O'Sullivan BJ et al (2006) IL-1 beta breaks tolerance through expansion of CD25? effector T cells. J Immunol 176(12): 7278-7287
23. Hannum CH et al (1990) Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 343(6256): 336-340
24. Carter DB et al (1990) Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature 344(6267):633-638
25. Aksentijevich I et al (2009) An auto inflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 360(23):2426-2437
26. Reddy S et al (2009) An auto inflammatory disease due to homozygous deletion of the IL1RN locus. N Engl J Med 360(23):2438-2444
27. Masters SL et al (2009) Horror autoinflammaticus: The molecular pathophysiology of auto inflammatory disease. Annu Rev Immunol 27:621-668
28. Netea MG et al (2009) Differential requirement for the activation of the inflammasome for processing and release of IL-1 beta in monocytes and macrophages. Blood 113(10):2324-2335
29. Hiscott J et al (1993) Characterization of a functional NF-kappa B site in the human interleukin 1 beta promoter: Evidence for a positive autoregulatory loop. Mol Cell Biol 13(10):6231-6240
30. Bauernfeind FG et al (2009) Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol 183(2):787-791
31. Bauernfeind F et al (2011) Inflammasomes: Current understanding and open questions. Cell Mol Life Sci 68(5):765-783
32. Guarda G et al (2011) Differential expression of NLRP3 among hematopoietic cells. J Immunol 186(4):2529-2534
33. Lu JY, Sadri N, Schneider RJ (2006) Endotoxic shock in AUF1 knockout mice mediated by failure to degrade proinflammatory cytokine mRNAs. Genes Dev 20(22):3174-3184
34. Fenton MJ et al (1987) Transcriptional regulation of the human prointerleukin 1 beta gene. J Immunol 138(11):3972-3979
35. Schindler R, Clark BD, Dinarello CA (1990) Dissociation between interleukin-1 betamRNAand protein synthesis in human peripheral blood mononuclear cells. J Biol Chem 265(18): 10232-10237
36. Schindler R, Gelfand JA, Dinarello CA (1990) Recombinant C5a stimulates transcription rather than translation of interleukin-1 (IL-1) and tumor necrosis factor: Translational signal provided by lipopolysaccharide or IL-1 itself. Blood 76(8): 1631-1638
37. Kaspar RL, Gehrke L (1994) Peripheral blood mononuclear cells stimulated with C5a or lipopolysaccharide to synthesize equivalent levels of IL-1 beta mRNA show unequal IL-1 beta protein accumulation but similar polyribosome profiles. J Immunol 153(1):277-286
38. Mosley B et al (1987) The interleukin-1 receptor binds the human interleukin-1 alpha precursor but not the interleukin-1 beta precursor. J Biol Chem 262(7):2941-2944
39. Thornberry NA et al (1992) A novel hetero dimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature 356(6372):768-774
40. Kuida K et al (1995) Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science 267(5206):2000-2003
41. Li P et al (1995) Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock. Cell 80(3):401-411
42. Martinon F, Burns K, Tschopp J (2002) The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10(2):417-426
43. Narayan S et al (2011) Octacalcium phosphate crystals induce inflammation in vivo through interleukin-1 but independent of the NLRP3 inflammasome in mice. Arthritis Rheum 63(2): 422-433
44. Fettelschoss A et al (2011) Inflammasome activation and IL-1beta target IL-1alpha for secretion as opposed to surface expression. Proc Natl Acad Sci USA 108(44):18055-18060
45. Martinon F, Mayor A, Tschopp J (2009) The inflammasomes: Guardians of the body. Annu Rev Immunol 27:229-265
46. Davis BK, Wen H, Ting JP (2011) The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol 29:707-735
47. Suzuki T et al (2007) Differential regulation of caspase-1 activation, pyroptosis, and autophagy via Ipaf and ASC in Shigellainfected macrophages. PLoS Pathog 3(8):e111
48. Lightfield KL et al (2008) Critical function for Naip5 in inflammasome activation by a conserved carboxy-terminal domain of flagellin. Nat Immunol 9(10):1171-1178
49. Kofoed EM, Vance RE (2011) Innate immune recognition of bacterial ligands by NAIPs determines inflammasome specificity. Nature 477(7366):592-595
50. Mariathasan S et al (2004) Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 430(6996):213-218
51. Boyden ED, Dietrich WF (2006) Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nat Genet 38(2): 240-244
52. Menu P, Vince JE (2011) The NLRP3 inflammasome in health and disease: The good, the bad and the ugly. Clin Exp Immunol 166(1):1-15
53. Tschopp J, Schroder K (2010) NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production? Nat Rev Immunol 10(3):210-215
54. Chen G et al (2009) NOD-like receptors: Role in innate immunity and inflammatory disease. Annu Rev Pathol 4:365-398
55. Elinav E et al (2011) NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 145(5):745-757
56. Jeru I et al (2011) Identification and functional consequences of a recurrent NLRP12 missense mutation in periodic fever syndromes. Arthritis Rheum 63(5):1459-1464
57. Borghini S et al (2011) Clinical presentation and pathogenesis of cold-induced auto inflammatory disease in a family with recurrence of an NLRP12 mutation. Arthritis Rheum 63(3):830-839
58. Schattgen SA, Fitzgerald KA (2011) The PYHIN protein family as mediators of host defenses. Immunol Rev 243(1):109-118
59. Billiau A (2006) Anti-inflammatory properties of type I interferons. Antivir Res 71(2-3):108-116
60. Schlaak JF et al (2002) Cell-type and donor-specific transcriptional responses to interferon-alpha. Use of customized gene arrays. J Biol Chem 277(51):49428-49437
61. Honda K, Taniguchi T (2006) IRFs: Master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 6(9):644-658
62. Goodbourn S, Didcock L, Randall RE (2000) Interferons: Cell signalling, immune modulation, antiviral response and virus countermeasures. J Gen Virol 81(Pt 10):2341-2364
63. Basler CF, Garcia-Sastre A (2002) Viruses and the type I interferon antiviral system: Induction and evasion. Int Rev Immunol 21(4-5):305-337
64. Platanias LC (2005) Mechanisms of type-I-and type-II-interferon-mediated signalling. Nat Rev Immunol 5(5):375-386
65. Young HA, Bream JH (2007) IFN-gamma: Recent advances in understanding regulation of expression, biological functions, and clinical applications. Curr Top Microbiol Immunol 316: 97-117
66. Zhu J, Yamane H, Paul WE (2010) Differentiation of effector CD4 T cell populations. Annu Rev Immunol 28:445-489
67. Hwang ES (2010) Transcriptional regulation of T helper 17 cell differentiation. Yonsei Med J 51(4):484-491
68. Schroder K et al (2004) Interferon-gamma: An overview of signals, mechanisms and functions. J Leukoc Biol 75(2):163-189
69. Coccia EM et al (2004) Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol 34(3):796-805
70. Witte K et al (2010) IL-28A, IL-28B, and IL-29: Promising cytokines with type I interferon-like properties. Cytokine Growth Factor Rev 21(4):237-251
71. Sheppard P et al (2003) IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4(1):63-68
72. Kotenko SV et al (2003) IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4(1):69-77
73. Uze G, Monneron D (2007) IL-28 and IL-29: Newcomers to the interferon family. Biochimie 89(6-7):729-734
74. Nickolaus P, Zawatzky R (1994) Inhibition by interleukin-4 of constitutive beta interferon synthesis in mouse macrophages. J Virol 68(10):6763-6766
75. Bautista EM et al (2005) Constitutive expression of alpha interferon by skin dendritic cells confers resistance to infection by foot-and-mouth disease virus. J Virol 79(8):4838-4847
76. Lienenklaus S et al (2009) Novel reporter mouse reveals constitutive and inflammatory expression of IFN-beta in vivo. J Immunol 183(5):3229-3236
77. Pulverer JE et al (2010) Temporal and spatial resolution of type I and III interferon responses in vivo. J Virol 84(17):8626-8638
78. Taniguchi T, Takaoka A (2001) A weak signal for strong responses: Interferon-alpha/beta revisited. Nat Rev Mol Cell Biol 2(5):378-386
79. Weber F et al (2006) Double-stranded RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable amounts by negative-strand RNA viruses. J Virol 80(10):5059-5064
80. McCartney SA, Colonna M (2009) Viral sensors: Diversity in pathogen recognition. Immunol Rev 227(1):87-94
81. Meylan E et al (2005) Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437(7062):1167-1172
82. Merika M, Thanos D (2001) Enhanceosomes. Curr Opin Genet Dev 11(2):205-208
83. Schafer SL et al (1998) Regulation of type I interferon gene expression by interferon regulatory factor-3. J Biol Chem 273(5):2714-2720
84. Honda K et al (2005) IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434(7034):772-777
85. Rathinam VA, Fitzgerald KA (2011) Innate immune sensing of DNA viruses. Virology 411(2):153-162
86. Ishikawa H, Barber GN (2011) The STING pathway and regulation of innate immune signaling in response to DNA pathogens. Cell Mol Life Sci 68(7):1157-1165
87. Hornung V et al (2002) Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 168(9):4531-4537
88. Takeda K, Kaisho T, Akira S (2003) Toll-like receptors. Annu Rev Immunol 21:335-376
89. Takeuchi O, Akira S (2009) Innate immunity to virus infection. Immunol Rev 227(1):75-86
90. Colonna M, Trinchieri G, Liu YJ (2004) Plasmacytoid dendritic cells in immunity. Nat Immunol 5(12):1219-1226
91. Colonna M, Krug A, Cella M (2002) Interferon-producing cells: On the front line in immune responses against pathogens. Curr Opin Immunol 14(3):373-379
92. Silvennoinen O et al (1993) Interferon-induced nuclear signalling by Jak protein tyrosine kinases. Nature 366(6455):583-585
93. Borden EC et al (2007) Interferons at age 50: Past, current and future impact on biomedicine. Nat Rev Drug Discov 6(12):975-990
94. de Veer MJ et al (2001) Functional classification of interferonstimulated genes identified using microarrays. J Leukoc Biol 69(6):912-920
95. Harada H, Taniguchi T, Tanaka N (1998) The role of interferon regulatory factors in the interferon system and cell growth control. Biochimie 80(8-9):641-650
96. Joshi S et al (2010) Mechanisms of mRNA translation of interferon stimulated genes. Cytokine 52(1-2):123-127
97. CrowMK(2010) Type I interferon in organ-targeted autoimmune and inflammatory diseases. Arthritis Res Ther 12(Suppl 1):S5
98. Choubey D, Moudgil KD (2011) Interferons in autoimmune and inflammatory diseases: Regulation and roles. J Interferon Cytokine Res 31(12):857-865
99. Kalie E et al (2008) The stability of the ternary interferonreceptor complex rather than the affinity to the individual subunits dictates differential biological activities. J Biol Chem 283(47):32925-32936
100. Bowie AG, Unterholzner L (2008) Viral evasion and subversion of pattern-recognition receptor signalling. Nat Rev Immunol 8(12):911-922
101. Garcia MA, Meurs EF, Esteban M (2007) The ds RNA protein kinase PKR: Virus and cell control. Biochimie 89(6-7):799-811
102. Hovanessian AG (2007) On the discovery of interferon-inducible, double-stranded RNA activated enzymes: The 20-50oligoadenylate synthetases and the protein kinase PKR. Cytokine Growth Factor Rev 18(5-6):351-361
103. Randall RE, Goodbourn S (2008) Interferons and viruses: An inter play between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 89(Pt 1):1-47
104. Sadler AJ, Williams BR (2008) Interferon-inducible antiviral effectors. Nat Rev Immunol 8(7):559-568
105. Mattei F, Schiavoni G, Tough DF (2010) Regulation of immune cell homeostasis by type I interferons. Cytokine Growth Factor Rev 21(4):227-236
106. Longhi MP et al (2009) Dendritic cells require a systemic type I interferon response to mature and induce CD4? Th1 immunity with poly IC as adjuvant. J Exp Med 206(7):1589-1602
107. Le Bon A et al (2003) Cross-priming of CD8? T cells stimulated by virus-induced type I interferon. Nat Immunol 4(10): 1009-1015
108. Theofilopoulos AN et al (2005) Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 23:307-336
109. Gallucci S, Lolkema M, Matzinger P (1999) Natural adjuvants: Endogenous activators of dendritic cells. Nat Med 5(11):1249-1255
110. Brinkmann V et al (1993) Interferon alpha increases the frequency of interferon gamma-producing human CD4? T cells. J Exp Med 178(5):1655-1663
111. Krug A et al (2003) CpG-A oligonucleotides induce a monocyte-derived dendritic cell-like phenotype that preferentially activates CD8 T cells. J Immunol 170(7):3468-3477
112. Persky ME, Murphy KM, Farrar JD (2005) IL-12, but not IFNalpha, promotes STAT4 activation and Th1 development in murine CD4? T cells expressing a chimeric murine/human Stat2 gene. J Immunol 174(1):294-301
113. Berenson LS et al (2006) Distinct characteristics of murine STAT4 activation in response to IL-12 and IFN-alpha. J Immunol 177(8):5195-5203
114. Matikainen S et al (2001) IFN-alpha and IL-18 synergistically enhance IFN-gamma production in human NK cells: Differential regulation of Stat4 activation and IFN-gamma gene expression by IFN-alpha and IL-12. Eur J Immunol 31(7):2236-2245
115. Rogge L et al (1997) Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J Exp Med 185(5):825-831
116. Huber JP et al (2010) Cutting edge: Type I IFN reverses human Th2 commitment and stability by suppressing GATA3. J Immunol 185(2):813-817
117. Harrington LE et al (2005) Interleukin 17-producing CD4? effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6(11):1123-1132
118. Moschen AR et al (2008) Interferon-alpha controls IL-17 expression in vitro and in vivo. Immunobiology 213(9-10): 779-787
119. Sweeney CM et al (2011) IL-27 mediates the response to IFNbeta therapy in multiple sclerosis patients by inhibiting Th17 cells. Brain Behav Immun 25(6):1170-1181
120. Ramgolam VS et al (2009) IFN-beta inhibits human Th17 cell differentiation. J Immunol 183(8):5418-5427
121. Geng Y et al (1995) Tumor suppressor activity of the human consensus type I interferon gene. Cytokines Mol Ther 1(4):289-300
122. TanakaNet al (1998) Type I interferons are essential mediators of apoptotic death in virally infected cells. Genes Cells 3(1):29-37
123. Marrack P, Kappler J, Mitchell T (1999) Type I interferons keep activated T cells alive. J Exp Med 189(3):521-530
124. Davis AM et al (2008) Cutting edge: A T-bet-independent role for IFN-alpha/beta in regulating IL-2 secretion in human CD4? central memory T cells. J Immunol 181(12):8204-8208
125. Curtsinger JM et al (2005) Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol 174(8):4465-4469
126. Le Bon A et al (2006) Direct stimulation of T cells by type I IFN enhances the CD8? T cell response during cross-priming. J Immunol 176(8):4682-4689
127. Ronnblom L, Alm GV, Eloranta ML (2009) Type I interferon and lupus. Curr Opin Rheumatol 21(5):471-477
128. Zhang X et al (1998) Potent and selective stimulation of memory-phenotype CD8? T cells in vivo by IL-15. Immunity 8(5):591-599
129. Mattei F et al (2001) IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation. J Immunol 167(3):1179-1187
130. Di Sabatino A et al (2011) Role of IL-15 in immune-mediated and infectious diseases. Cytokine Growth Factor Rev 22(1): 19-33
131. Groom JR, Luster AD (2011) CXCR3 ligands: Redundant, collaborative and antagonistic functions. Immunol Cell Biol 89(2):207-215
132. Le Bon A et al (2001) Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14(4):461-470
133. Jego G et al (2003) Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19(2):225-234
134. Badr G et al (2010) Type I interferon (IFN-alpha/beta) rescues B-lymphocytes from apoptosis via PI3Kdelta/Akt, Rho-A, NFkappaB and Bcl-2/Bcl(XL). Cell Immunol 263(1):31-40
135. Bekisz J et al (2010) Antiproliferative properties of type I and type II interferon. Pharmaceuticals 3(4):994-1015
136. Rath PC, Aggarwal BB (2001) Antiproliferative effects of IFNalpha correlate with the downregulation of nuclear factor-kappa B in human Burkitt lymphoma Daudi cells. J Interferon Cytokine Res 21(7):523-528
137. Takaoka A et al (2003) Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 424(6948):516-523
138. Fuertes Marraco SA et al (2011) Type I interferon drives dendritic cell apoptosis via multiple BH3-only proteins following activation by Poly IC in vivo. PLoS ONE 6(6):e20189
139. Eitz Ferrer P et al (2011) Induction of Noxa-mediated apoptosis by modified vaccinia virus Ankara depends on viral recognition by cytosolic helicases, leading to IRF-3/IFN-beta-dependent induction of pro-apoptotic Noxa. PLoS Pathog 7(6):e1002083
140. Lee SB, Esteban M (1994) The interferon-induced doublestranded RNA-activated protein kinase induces apoptosis. Virology 199(2):491-496
141. Gil J, Esteban M (2000) The interferon-induced protein kinase (PKR), triggers apoptosis through FADD-mediated activation of caspase 8 in a manner independent of Fas and TNF-alpha receptors. Oncogene 19(32):3665-3674
142. Hsu LC et al (2004) The protein kinase PKR is required for macrophage apoptosis after activation of Toll-like receptor 4. Nature 428(6980):341-345
143. Chawla-Sarkar M et al (2003) Apoptosis and interferons: Role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8(3):237-249
144. Salaun B, Romero P, Lebecque S (2007) Toll-like receptors' two-edged sword: When immunity meets apoptosis. Eur J Immunol 37(12):3311-3318
145. Haller O, Kochs G, Weber F (2006) The interferon response circuit: Induction and suppression by pathogenic viruses. Virology 344(1):119-130
146. Besch R et al (2009) Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J Clin Invest 119(8):2399-2411
147. Hasan UA et al (2007) Cell proliferation and survival induced by Toll-like receptors is antagonized by type I IFNs. Proc Natl Acad Sci USA 104(19):8047-8052
148. Colonna M (2006) Toll-like receptors and IFN-alpha: Partners in autoimmunity. J Clin Invest 116(9):2319-2322
149. Hall JC, Rosen A (2010) Type I interferons: Crucial participants in disease amplification in autoimmunity. Nat Rev Rheumatol 6(1):40-49
150. Akeno N et al (2011) IFN-alpha mediates the development of autoimmunity both by direct tissue toxicity and through immune cell recruitment mechanisms. J Immunol 186(8):4693-4706
151. Borg FA, Isenberg DA (2007) Syndromes and complications of interferon therapy. Curr Opin Rheumatol 19(1):61-66
152. Vallin H et al (1999) Anti-double-stranded DNA antibodies and immuno stimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus. J Immunol 163(11):6306-6313
153. Bave U et al (2003) Fc gamma RIIa is expressed on natural IFNalpha-producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus IgG. J Immunol 171(6):3296-3302
154. Means TK et al (2005) Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 115(2):407-417
155. Kahlenberg JM et al (2011) Inflammasome activation of IL-18 results in endothelial progenitor cell dysfunction in systemic lupus erythematosus. J Immunol 187(11):6143-6156
156. Panchanathan R et al (2010) Aim2 deficiency stimulates the expression of IFN-inducible Ifi202, a lupus susceptibility murine gene within the Nba2 autoimmune susceptibility locus. J Immunol 185(12):7385-7393
157. Martens HA et al (2009) An extensive screen of the HLA region reveals an independent association of HLA class I and class II with susceptibility for systemic lupus erythematosus. Scand J Rheumatol 38(4):256-262
158. Sigurdsson S et al (2005) Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet 76(3):528-537
159. Santiago-Raber ML et al (2003) Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 197(6):777-788
160. Braun D, Geraldes P, Demengeot J (2003) Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice. J Autoimmun 20(1):15-25
161. Hron JD, Peng SL (2004) Type I IFN protects against murine lupus. J Immunol 173(3):2134-2142
162. Wu X, Peng SL (2006) Toll-like receptor 9 signaling protects against murine lupus. Arthritis Rheum 54(1):336-342
163. Vakaloglou KM, Mavragani CP (2011) Activation of the type I interferon pathway in primary Sjogren's syndrome: An update. Curr Opin Rheumatol 23(5):459-464
164. van der Pouw Kraan TC et al (2007) Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: Assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis 66(8):1008-1014
165. Harboe E et al (2009) Fatigue in primary Sjogren's syndrome-a link to sickness behaviour in animals? Brain Behav Immun 23(8):1104-1108
166. Meijer JM et al (2007) The future of biologic agents in the treatment of Sjogren's syndrome. Clin Rev Allergy Immunol 32(3):292-297
167. Tak PP (2004) IFN-beta in rheumatoid arthritis. Front Biosci 9:3242-3247
168. Ying F et al (2011) Type I IFN protects against antigen-induced arthritis. Eur J Immunol 41(6):1687-1695
169. van Holten J et al (2004) Treatment with recombinant interferon-beta reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res Ther 6(3):R239-R249
170. Tak PP et al (1999) The effects of interferon beta treatment on arthritis. Rheumatology (Oxford) 38(4):362-369
171. Vervoordeldonk MJ, Aalbers CJ, Tak PP (2009) Interferon beta for rheumatoid arthritis: New clothes for an old kid on the block. Ann Rheum Dis 68(2):157-158
172. Koltai M, Meos E (1973) Inhibition of the acute inflammatory response by interferon inducers. Nature 242(5399):525-526
173. Triantaphyllopoulos KA et al (1999) Amelioration of collageninduced arthritis and suppression of interferon-gamma, interleukin-12, and tumor necrosis factor alpha production by interferon-beta gene therapy. Arthritis Rheum 42(1):90-99
174. Hirsch MS et al (1974) Immunosuppressive effects of an interferon preparation in vivo. Transplantation 17(2):234-236
175. Veldhuis WB et al (2003) Interferon-beta prevents cytokineinduced neutrophil infiltration and attenuates blood-brain barrier disruption. J Cereb Blood Flow Metab 23(9):1060-1069
176. Yu M et al (1996) Interferon-beta inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis. J Neuroimmunol 64(1):91-100
177. Kraus J et al (2004) Interferon-beta stabilizes barrier characteristics of brain endothelial cells in vitro. Ann Neurol 56(2): 192-205
178. Trinchieri G (2010) Type I interferon: Friend or foe? J Exp Med 207(10):2053-2063
179. Sharma S et al (2011) Innate immune recognition of an AT-rich stem-loop DNA motif in the Plasmodium falciparum genome. Immunity 35(2):194-207
180. Henry T et al (2010) Type I IFN signaling constrains IL-17A/F secretion by gammadelta T cells during bacterial infections. J Immunol 184(7):3755-3767
181. Auerbuch V et al (2004) Mice lacking the type I interferon receptor are resistant to Listeria monocytogenes. J Exp Med 200(4):527-533
182. O'Connell RM et al (2004) Type I interferon production enhances susceptibility to Listeria monocytogenes infection. J Exp Med 200(4):437-445
183. Xin L et al (2010) Type I IFN receptor regulates neutrophil functions and innate immunity to Leishmania parasites. J Immunol 184(12):7047-7056
184. Mayer-Barber KD et al (2011) Innate and adaptive interferons suppress IL-1 alpha and IL-1 beta production by distinct pulmonary myeloid subsets during Mycobacterium tuberculosis infection. Immunity 35(6):1023-1034
185. Manca C et al (2005) Hypervirulent M. tuberculosis W/Beijing strains upregulate type I IFNs and increase expression of negative regulators of the Jak-Stat pathway. J Interferon Cytokine Res 25(11):694-701
186. Berry MP et al (2010) An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466(7309):973-977
187. Shahangian A et al (2009) Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J Clin Invest 119(7):1910-1920
188. Guarda G et al (2011) Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 34(2): 213-223
189. Worthington M, Hasenclever HF (1972) Effect of an interferon stimulator, polyinosinic: Polycytidylic acid, on experimental fungus infections. Infect Immun 5(2):199-202
190. Jensen J, Vazquez-Torres A, Balish E (1992) Poly (I. C)-induced interferons enhance susceptibility of SCID mice to systemic candidiasis. Infect Immun 60(11):4549-4557
191. Reznikov LL et al (1998) Spontaneous and inducible cytokine responses in healthy humans receiving a single dose of IFNalpha2b: Increased production of interleukin-1 receptor antagonist and suppression of IL-1-induced IL-8. J Interferon Cytokine Res 18(10):897-903
192. Schindler R, Ghezzi P, Dinarello CA (1990) IL-1 induces IL-1. IV. IFN-gamma suppresses IL-1 but not lipopolysaccharideinduced transcription of IL-1. J Immunol 144(6):2216-2222
193. Guarda G, So A (2010) Regulation of inflammasome activity. Immunology 130(3):329-336
194. Huang Y, Blatt LM, Taylor MW (1995) Type 1 interferon as an antiinflammatory agent: Inhibition of lipopolysaccharideinduced interleukin-1 beta and induction of interleukin-1 receptor antagonist. J Interferon Cytokine Res 15(4):317-321
195. Coclet-Ninin J, Dayer JM, Burger D (1997) Interferon-beta not only inhibits interleukin-1 beta and tumor necrosis factor-alpha but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells. Eur Cytokine Netw 8(4):345-349
196. Zang YC et al (2004) Regulation of differentiation and functional properties of monocytes and monocyte-derived dendritic cells by interferon beta in multiple sclerosis. Mult Scler 10(5): 499-506
197. Byrnes AA et al (2001) Type I interferons and IL-12: Convergence and cross-regulation among mediators of cellular immunity. Eur J Immunol 31(7):2026-2034
198. Nagai T et al (2003) Timing of IFN-beta exposure during human dendritic cell maturation and naive Th cell stimulation has contrasting effects on Th1 subset generation: A role for IFNbeta-mediated regulation of IL-12 family cytokines and IL-18 in naive Th cell differentiation. J Immunol 171(10):5233-5243
199. Novikov A et al (2011) Mycobacterium tuberculosis triggers host type I IFN signaling to regulate IL-1{beta} production in human macrophages. J Immunol 187(5):2540-2547
200. Radwan M et al (2010) Tyrosine kinase 2 controls IL-1 beta production at the translational level. J Immunol 185(6):3544-3553
201. Bellocchio S et al (2004) The contribution of the Toll-like/IL-1 receptor superfamily to innate and adaptive immunity to fungal pathogens in vivo. J Immunol 172(5):3059-3069
202. Vonk AG et al (2006) Endogenous interleukin (IL)-1 alpha and IL-1 beta are crucial for host defense against disseminated candidiasis. J Infect Dis 193(10):1419-1426
203. Fremond CM et al (2007) IL-1 receptor-mediated signal is an essential component of MyD88-dependent innate response to Mycobacteriumtuberculosis infection. J Immunol 179(2):1178-1189
204. Mayer-Barber KD et al (2010) Caspase-1 independent IL-1 beta production is critical for host resistance to mycobacterium tuberculosis and does not require TLR signaling in vivo. J Immunol 184(7):3326-3330
205. Masters SL et al (2010) Regulation of interleukin-1 beta by interferon-gamma is species specific, limited by suppressor of cytokine signalling 1 and influences interleukin-17 production. EMBO Rep 11(8):640-646
206. Aman MJ et al (1994) Regulation of cytokine expression by interferon-alpha in human bone marrow stromal cells: Inhibition of hematopoietic growth factors and induction of interleukin-1 receptor antagonist. Blood 84(12):4142-4150
207. Chang EY et al (2007) Cutting edge: Involvement of the type I IFN production and signaling pathway in lipopolysaccharideinduced IL-10 production. J Immunol 178(11):6705-6709
208. de Waal Malefyt R et al (1991) Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med 174(5):1209-1220
209. Fiorentino DF et al (1991) IL-10 inhibits cytokine production by activated macrophages. J Immunol 147(11):3815-3822
210. Berg DJ et al (1996) Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(?) Th1-like responses. J Clin Invest 98(4):1010-1020
211. Wang H et al (2011) The role of glycogen synthase kinase 3 in regulating IFN-beta-mediated IL-10 production. J Immunol 186(2):675-684
212. Ziegler-Heitbrock L et al (2003) IFN-alpha induces the human IL-10 gene by recruiting both IFN regulatory factor 1 and Stat3. J Immunol 171(1):285-290
213. Wang P et al (1994) IL-10 inhibits transcription of cytokine genes in human peripheral blood mononuclear cells. J Immunol 153(2):811-816
214. Jenkins JK, Malyak M, Arend WP (1994) The effects of interleukin-10 on interleukin-1 receptor antagonist and interleukin-1 beta production in human monocytes and neutrophils. Lymphokine Cytokine Res 13(1):47-54
215. Fernandes-Alnemri T et al (2010) The AIM2 inflammasome is critical for innate immunity to Francisella tularensis. Nat Immunol 11(5):385-393
216. Rathinam VA et al (2010) The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol 11(5):395-402
217. Zwaferink H et al (2008) IFN-beta increases listeriolysin O-induced membrane permeabilization and death of macrophages. J Immunol 180(6):4116-4123
218. Veeranki S et al (2011) IFI16 protein mediates the anti-inflammatory actions of the type-I interferons through suppression of activation of caspase-1 by inflammasomes. PLoS ONE 6(10): E27040
219. Dienstag JL (2008) Hepatitis B virus infection. N Engl J Med 359(14):1486-1500
220. Foster GR (2010) Pegylated interferons for the treatment of chronic hepatitis C: Pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b. Drugs 70(2):147-165
221. Vezali E et al (2011) Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis? Clin Res Hepatol Gastroenterol 35(6-7):455-464
222. Yang J et al (2009) Interferon for the treatment of genital warts: A systematic review. BMC Infect Dis 9:156
223. Krown SE (2007) AIDS-associated Kaposi's sarcoma: Is there still a role for interferon alfa? Cytokine Growth Factor Rev 18(5-6):395-402
224. Kiladjian JJ, Mesa RA, Hoffman R (2011) The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood 117(18):4706-4715
225. Habermann TM, Rai K (2011) Historical treatments of in hairy cell leukemia, splenectomy and interferon: Past and current uses. Leuk Lymphoma 52(Suppl 2):18-20
226. Eggermont AM et al (2012) Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 48(2):218-25
227. Anderson DW et al (1992) Revised estimate of the prevalence of multiple sclerosis in the United States. AnnNeurol 31(3):333-336
228. Compston A, Coles A (2008) Multiple sclerosis. Lancet 372(9648):1502-1517
229. Kappos L et al (2007) Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: A 3-year follow-up analysis of the BENEFIT study. Lancet 370(9585):389-397
230. Durelli L et al (1994) Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology 44(3 Pt 1): 406-413
231. Squillacote D, Martinez M, Sheremata W (1996) Natural alpha interferon in multiple sclerosis: Results of three preliminary series. J Int Med Res 24(3):246-257
232. Kinnunen E et al (1993) Effects of recombinant alpha-2binterferon therapy in patients with progressive MS. Acta Neurol Scand 87(6):457-460
233. Larrey D et al (1989) Exacerbation of multiple sclerosis after the administration of recombinant human interferon alfa. JAMA 261(14):2065
234. Kataoka I et al (2002) Multiple sclerosis associated with interferon-alpha therapy for chronic myelogenous leukemia. Am J Hematol 70(2):149-153
235. Ben-Nun A, Wekerle H, Cohen IR (1981) The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol 11(3):195-199
236. Lassmann H, Wekerle H (2006) The pathology of multiple sclerosis. In: Compston A (ed) Mc Alpine's multiple sclerosis. Elsevier, London, pp 557-599
237. Babbe H et al (2000) Clonal expansions of CD8(?) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 192(3):393-404
238. Lucchinetti C et al (2000) Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 47(6):707-717
239. Glass CK et al (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140(6):918-934
240. Fernandez M, Montalban X, Comabella M (2010) Orchestrating innate immune responses in multiple sclerosis: Molecular players. J Neuroimmunol 225(1-2):5-12
241. Furlan R et al (1999) Caspase-1 regulates the inflammatory process leading to autoimmune demyelination. J Immunol 163(5):2403-2409
242. Shaw PJ et al (2010) Cutting edge: Critical role for PYCARD/ ASC in the development of experimental autoimmune encephalomyelitis. J Immunol 184(9):4610-4614
243. Gris D et al (2010) NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses. J Immunol 185(2):974-981
244. Matsuki T et al (2006) Abnormal T cell activation caused by the imbalance of the IL-1/IL-1R antagonist system is responsible for the development of experimental autoimmune encephalomyelitis. Int Immunol 18(2):399-407
245. Bhat R, Steinman L (2009) Innate and adaptive autoimmunity directed to the central nervous system. Neuron 64(1):123-132
246. Kaser A et al (1999) Interferon-beta 1b augments activationinduced T-cell death in multiple sclerosis patients. Lancet 353(9162):1413-1414
247. Christophi GP et al (2008) SHP-1 deficiency and increased inflammatory gene expression in PBMCs of multiple sclerosis patients. Lab Invest 88(3):243-255
248. Christophi GP et al (2009) Interferon-beta treatment in multiple sclerosis attenuates inflammatory gene expression through inducible activity of the phosphatase SHP-1. Clin Immunol 133(1):27-44
249. Dickensheets HL et al (1999) Interferons inhibit activation of STAT6 by interleukin 4 in human monocytes by inducing SOCS-1 gene expression. Proc Natl Acad Sci USA 96(19):10800-10805
250. Shiow LR et al (2006) CD69 acts downstream of interferonalpha/ beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature 440(7083):540-544
251. Kieseier BC, Archelos JJ, Hartung HP (2004) Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinases. Arch Neurol 61(6):929-932
252. Gilli F et al (2004) Neutralizing antibodies against IFN-beta in multiple sclerosis: Antagonization of IFN-beta mediated suppression of MMPs. Brain 127(Pt 2):259-268
253. Muraro PA et al (2000) VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis. J Neuroimmunol 111(1-2):186-194
254. Muraro PA et al (2004) Decreased integrin gene expression in patients with MS responding to interferon-beta treatment. J Neuroimmunol 150(1-2):123-131
255. Becher B, Segal BM (2011) Th17 cytokines in autoimmune neuro-inflammation. Curr Opin Immunol 26:707-712
256. Arnason BG (1999) Immunologic therapy of multiple sclerosis. Annu Rev Med 50:291-302
257. Sturzebecher S et al (2003) Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain 126(Pt 6):1419-1429
258. Axtell RC et al (2010) T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 16(4):406-412
259. Wang AG et al (2006) Early relapse in multiple sclerosisassociated optic neuritis following the use of interferon beta-1a in Chinese patients. Jpn J Ophthalmol 50(6):537-542
260. Walther EU, Hohlfeld R (1999) Multiple sclerosis: Side effects of interferon beta therapy and their management. Neurology 53(8):1622-1627
261. The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43(4):655-661
262. The IFNB Multiple Sclerosis Study Group, The University of British Columbia MS/MRI Analysis Group (1995) Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology 45(7):1277-1285
263. Paty DW, Li DK, UBC MS/MRI Study Group, The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43(4):662-667
264. Jacobs LD, The Multiple Sclerosis Collaborative Research Group (MSCRG) et al (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39(3):285-294
265. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352(9139):1498-1504
266. European Study Group (1998) Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 352(9139):1491-1497
267. Reder AT et al (2010) Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS. Neurology 74(23):1877-1885
268. Tremlett HL, Oger J (2004) Elevated aminotransferases during treatment with interferon-beta for multiple sclerosis: Actions and outcomes. Mult Scler 10(3):298-301
269. Yoshida EM et al (2001) Fulminant liver failure during interferon beta treatment of multiple sclerosis. Neurology 56(10):1416
270. Pulicken M et al (2006) Unmasking of autoimmune hepatitis in a patient with MS following interferon beta therapy. Neurology 66(12):1954-1955
271. Fragoso YD et al (2010) Severe depression, suicide attempts, and ideation during the use of interferon beta by patients with multiple sclerosis. Clin Neuropharmacol 33(6):312-316
272. Borras C et al (1999) Emotional state of patients with relapsingremitting MS treated with interferon beta-1b. Neurology 52(8):1636-1639
273. Abdul-Ahad AK et al (1997) Incidence of antibodies to interferon-beta in patients treated with recombinant human interferon-beta 1a from mammalian cells. Cytokines Cell Mol Ther 3(1):27-32
274. Rudick RA, Multiple Sclerosis Collaborative Research Group (MSCRG) et al (1998) Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology 50(5):1266-1272
275. The IFNB Multiple Sclerosis Study Group, The University of British Columbia MS/MRI Analysis Group (1996) Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years. Neurology 47(4):889-894
276. Ross C, Danish Multiple Sclerosis Study Group et al (2000) Immunogenicity of interferon-beta in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administration. Ann Neurol 48(5):706-712
277. Sorensen PS et al (2003) Clinical importance of neutralising antibodies against interferon beta in patients with relapsingremitting multiple sclerosis. Lancet 362(9391):1184-1191
278. McGonagle D, McDermott MF (2006) A proposed classification of the immunological diseases. PLoS Med 3(8):e297
279. Hoffman HM et al (2001) Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome andMuckle-Wells syndrome. Nat Genet 29(3):301-305
280. Hawkins PN et al (2004) Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 50(2):607-612
281. Goldbach-Mansky R et al (2006) Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 355(6):581-592
282. Lachmann HJ et al (2009) Use of canakinumab in the cryopyrinassociated periodic syndrome. N Engl J Med 360(23): 2416-2425
283. Lepore L et al (2010) Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra. J Pediatr 157(2):310-315e1
284. Neven B et al (2010) Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 62(1):258-267
285. Kuemmerle-Deschner JB et al (2011) Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. Arthritis Rheum 63(3):840-849
286. The International FMF Consortium (1947) Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 90(4):797-807
287. French Familial Mediterranean fever Consortium (1997) A candidate gene for familial Mediterranean fever. Nat Genet 17(1):25-31
288. Rozenbaum M et al (1992) Decreased interleukin 1 activity released from circulating monocytes of patients with familial Mediterranean fever during in vitro stimulation by lipopolysaccharide. J Rheumatol 19(3):416-418
289. Papin S et al (2007) The SPRY domain of pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1beta processing. Cell Death Differ 14(8):1457-1466
290. Chae JJ et al (2011) Gain-of-function pyrin mutations induce NLRP3 protein-independent interleukin-1beta activation and severe autoinflammation in mice. Immunity 34(5):755-768
291. Mitroulis I et al (2008) Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient. Neth J Med 66(11):489-491
292. Calligaris L et al (2008) The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur J Pediatr 167(6):695-696
293. Ozen S et al (2011) Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J Rheumatol 38(3):516-518
294. Meinzer U et al (2011) Interleukin-1 targeting drugs in familial Mediterranean fever: A case series and a review of the literature. Semin Arthritis Rheum 65(2):265-271
295. Bilginer Y, Ayaz NA, Ozen S (2010) Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behcet's disease. Clin Rheumatol 29(2):209-210
296. Tweezer-Zaks N et al (2008) Interferon-alpha as a treatment modality for colchicine-resistant familial Mediterranean fever. J Rheumatol 35(7):1362-1365
297. Hugot JP et al (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411(6837): 599-603
298. Ogura Y et al (2001) A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411(6837): 603-606
299. Barrett JC et al (2008) Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 40(8):955-962
300. Fisher SA et al (2008) Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nat Genet 40(6):710-712
301. Franke A et al (2008) Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. Nat Genet 40(6):713-715
302. Cho JH (2008) The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol 8(6):458-466
303. Massey DC, Parkes M (2007) Genome-wide association scanning highlights two autophagy genes, ATG16L1 and IRGM, as being significantly associated with Crohn's disease. Autophagy 3(6):649-651
304. Saitoh T et al (2008) Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature 456(7219):264-268
305. Travassos LH et al (2010) Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 11(1):55-62
306. Maeda S et al (2005) Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science 307(5710):734-738
307. Franke A et al (2008) Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet 40(11):1319-1323
308. Glocker EO et al (2009) Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 361(21):2033-2045
309. Oussalah A, Danese S, Peyrin-Biroulet L (2010) Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases: A systematic review. Curr Drug Targets 11(2):156-175
310. Sumer N, Palabiyikoglu M (1995) Induction of remission by interferon-alpha in patients with chronic active ulcerative colitis. Eur J Gastroenterol Hepatol 7(7):597-602
311. Nikolaus S et al (2003) Interferon beta-1a in ulcerative colitis: A placebo controlled, randomised, dose escalating study. Gut 52(9):1286-1290
312. Tilg H, Kaser A (2004) Type I interferons and their therapeutic role in Th2-regulated inflammatory disorders. Expert Opin Biol Ther 4(4):469-481
313. de Menthon M et al (2009) HLA-B51/B5 and the risk of Behcet's disease: A systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum 61(10):1287-1296
314. Remmers EF et al (2010) Genome-wide association study identifies variants in the MHC class I, IL10, and IL23RIL12RB2 regions associated with Behcet's disease. Nat Genet 42(8):698-702
315. Yurdakul S, Yazici H (2008) Behcet's syndrome. Best Pract Res Clin Rheumatol 22(5):793-809
316. Sfikakis PP et al (2007) Anti-TNF therapy in the management of Behcet's disease-review and basis for recommendations. Rheumatology (Oxford) 46(5):736-741
317. Melikoglu M et al (2005) Short-term trial of etanercept in Behcet's disease: A double blind, placebo controlled study. J Rheumatol 32(1):98-105
318. Botsios C et al (2008) Resistant Behcet disease responsive to anakinra. Ann Intern Med 149(4):284-286
319. Kotter I et al (2004) The use of interferon alpha in Behcet disease: Review of the literature. Semin Arthritis Rheum 33(5):320-335
320. Sheikh A, Strachan DP (2004) The hygiene theory: Fact or fiction? Curr Opin Otolaryngol Head Neck Surg 12(3):232-236
321. Hammad H, Lambrecht BN (2008) Dendritic cells and epithelial cells: Linking innate and adaptive immunity in asthma. Nat Rev Immunol 8(3):193-204
322. Lee HC, Ziegler SF (2007) Inducible expression of the proallergic cytokine thymic stromal lymphopoietin in airway epithelial cells is controlled by NFkappaB. Proc Natl Acad Sci USA 104(3):914-919
323. Allakhverdi Z et al (2007) Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J Exp Med 204(2):253-258
324. Rusznak C et al (2001) Interaction of cigarette smoke and house dust mite allergens on inflammatory mediator release from primary cultures of human bronchial epithelial cells. Clin Exp Allergy 31(2):226-238
325. Nakamura Y et al (2009) Mast cells mediate neutrophil recruitment and vascular leakage through the NLRP3 inflammasome in histamine-independent urticaria. J Exp Med 206(5):1037-1046
326. Okada S et al (1995) Potential role of interleukin-1 in allergeninduced late asthmatic reactions in guinea pigs: Suppressive effect of interleukin-1 receptor antagonist on late asthmatic reaction. J Allergy Clin Immunol 95(6):1236-1245
327. Schmitz N, Kurrer M, Kopf M (2003) The IL-1 receptor 1 is critical for Th2 cell type airway immune responses in a mild but not in a more severe asthma model. Eur J Immunol 33(4):991-1000
328. Nakae S et al (2003) IL-1 is required for allergen-specific Th2 cell activation and the development of airway hypersensitivity response. Int Immunol 15(4):483-490
329. Johnson VJ, Yucesoy B, Luster MI (2005) Prevention of IL-1 signaling attenuates airway hyperresponsiveness and inflammation in a murine model of toluene diisocyanate-induced asthma. J Allergy Clin Immunol 116(4):851-858
330. Li T et al (2006) Pharmacokinetics and anti-asthmatic potential of non-parenterally administered recombinant human interleukin-1 receptor antagonist in animal models. J Pharmacol Sci 102(3):321-330
331. Wang CC et al (2006) Adenovirus expressing interleukin-1 receptor antagonist alleviates allergic airway inflammation in a murine model of asthma. Gene Ther 13(19):1414-1421
332. Idzko M et al (2007) Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. Nat Med 13(8):913-919
333. Eisenbarth SC et al (2008) Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453(7198):1122-1126
334. Kool M et al (2008) Cutting edge: Alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol 181(6):3755-3759
335. KoolMet al (2011) An unexpected role for uric acid as an inducer of T helper 2 cell immunity to inhaled antigens and inflammatory mediator of allergic asthma. Immunity 34(4):527-540
336. Simon HU et al (2003) Clinical and immunological effects of low-dose IFN-alpha treatment in patients with corticosteroidresistant asthma. Allergy 58(12):1250-1255
337. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144(5):646-674
338. Apte RN et al (2006) The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 25(3):387-408
339. Sidky YA, Borden EC (1987) Inhibition of angiogenesis by interferons: Effects on tumor-and lymphocyte-induced vascular responses. Cancer Res 47(19):5155-5161
340. Tanaka T et al (2000) Induction ofVEGFgene transcription by IL-1 beta is mediated through stress-activated MAP kinases and Sp1 sites in cardiac myocytes. J Mol Cell Cardiol 32(11):1955-1967
341. El Awad B et al (2000) Hypoxia and interleukin-1beta stimulate vascular endothelial growth factor production in human proximal tubular cells. Kidney Int 58(1):43-50
342. Jung YD et al (2001) Vascular endothelial growth factor is upregulated by interleukin-1 beta in human vascular smooth muscle cells via the P38 mitogen-activated protein kinase pathway. Angiogenesis 4(2):155-162
343. Voronov E, Carmi Y, Apte RN (2007) Role of IL-1-mediated inflammation in tumor angiogenesis. Adv Exp Med Biol 601:265-270
344. Moosig F et al (2004) IL-1RA in refractory systemic lupus erythematosus. Lupus 13(8):605-606
345. Ostendorf B et al (2005) Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis 64(4):630-633
346. Voronov E et al (2006) IL-1 beta-deficient mice are resistant to induction of experimentalSLE. Eur Cytokine Netw17(2):109-116
347. Davis LS, Hutcheson J, Mohan C (2011) The role of cytokines in the pathogenesis and treatment of systemic lupus erythematosus. J Interferon Cytokine Res 31(10):781-789